SCHEMBL29655360

SCHEMBL29655360

C/C(=C\CO)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](OC(=O)Cc2ccc(O)c(O)c2)[C@H]1OC(=O)Cc1ccc(O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC5A1 P13866 3/20 0.41
▸ PRKCA P17252 3/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ CYP19A1 P11511 2/20 0.40
▸ SLC28A3 Q9HAS3 3/20 0.38
▸ PPARG P37231 1/20 0.38
▸ PPARD Q03181 1/20 0.38
▸ PPARA Q07869 1/20 0.38
▸ HSD17B10 Q99714 3/20 0.38
▸ HPGD P15428 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ SLC28A2 O43868 1/20 0.38
▸ SLC5A2 P31639 1/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29655349 1.00 SLC5A1 (0.41) SLC5A1PRKCAPTPN1CYP19A1SLC28A3
SCHEMBL29655308 0.96 PRKCA (0.42) SLC5A1PRKCAPTPN1CYP19A1SLC28A3
SCHEMBL29655306 0.94 LGALS8 (0.41) SLC5A1PTPN1SLC28A3HSD17B10HPGD
SCHEMBL29655356 0.93 PRKCA (0.38) SLC5A1PRKCAPTPN1CYP19A1L3MBTL1
SCHEMBL29655336 0.83 PRKCA (0.42) PRKCAPTPN1CYP19A1HSD17B10CYP3A4
SCHEMBL28481755 0.70 PRKCA (0.70) PRKCACYP19A1PPARGPPARDPPARA
SCHEMBL17284917 0.64 PRKCA (0.67) PRKCACYP19A1HSD17B10CYP3A4L3MBTL1
SCHEMBL17281059 0.64 PRKCA (0.67) PRKCACYP19A1HSD17B10CYP3A4L3MBTL1
SCHEMBL13075407 0.62 SLC5A2 (0.51) SLC5A1SLC28A3SLC5A2NPC1RAB9A
SCHEMBL15779695 0.61 PPARG (0.47) SLC5A1PRKCASLC28A3PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240108040-A1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED (US) 2024-04-04 — — US disclosed
US-11758933-B2 High intensity sweeteners FIRMENICH INCORPORATED (US) 2023-09-19 — — US disclosed
EP-3368542-B1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED (US) 2022-06-22 — — EP disclosed
US-11357246-B2 High intensity sweeteners FIRMENICH INCORPORATED (US) 2022-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108040-A1 HIGH INTENSITY SWEETENERS TAS2R40, TAS2R60, TAS1R1 SLC5A1 31/4885PRKCA 2722/4885PTPN1 3282/4885
US-11357246-B2 High intensity sweeteners TAS2R40, TAS2R60, TAS1R1 SLC5A1 31/4885PRKCA 2722/4885PTPN1 3282/4885
US-11758933-B2 High intensity sweeteners TAS2R40, TAS2R60, TAS1R1 SLC5A1 31/4885PRKCA 2722/4885PTPN1 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback